K. Gary Barnette - Concepedia

Concepedia

Author

K. Gary Barnette

Massachusetts General Hospital

Also Known As

K Gary Barnette, K. G. Barnette, K. GARY BARNETTE, K. Gary Barnette, K.G. Barnette, Kester G. Barnette

53

Publications

1.1K

Citations

12

H-Index

33

Concepts

All Affiliations

Massachusetts General Hospital Urology Associates University of Pennsylvania Regional Urology

KG

About

K. Gary Barnette is an author at Massachusetts General Hospital specializing in pharmacotherapy, pharmacology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	465
2	Health Sciences	3	3	431
3	Applied Physiology	2	2	406
4	Endocrinology	2	2	406
5	Diagnostic Sciences	1	1	25

K. Gary Barnette

×

13

Publications

1.1K

Citations

12

H-Index

	Year	Citations
The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trial James T. Dalton, K. Gary Barnette, Casey E. Bohl, Journal of Cachexia Sarcopenia and Muscle Healthy Elderly MenPharmacotherapyObesityMetabolic SyndromeBody Composition	2011	386
Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Matthew Smith, Ronald A. Morton, K. Gary Barnette, The Journal of Urology	2012	160
Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Matthew Smith, Ronald A. Morton, K. Gary Barnette, The Journal of Urology	2010	121
Toremifene Increases Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase 3 Clinical Study Matthew R. Smith, S. Bruce Malkowicz, Franklin Chu, The Journal of Urology	2007	117
Toremifene Improves Lipid Profiles in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase III Study Matthew R. Smith, S. Bruce Malkowicz, Franklin Chu, Journal of Clinical Oncology	2008	79
Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis K. Gary Barnette, Michael S. Gordon, Domingo Rodriguez, NEJM Evidence	2022	42
Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study. Carlo Palmieri, Hannah M. Linden, Stephen N. Birrell, Journal of Clinical Oncology Breast OncologyAr PositivityAr ExpressionPathologyPharmacotherapy	2021	34
A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor–targeting Agent Mark C. Markowski, Ronald Tutrone, Christopher Pieczonka, Clinical Cancer Research	2022	33
Factors Associated With Vertebral Fractures in Men Treated With Androgen Deprivation Therapy for Prostate Cancer Philip J. Saylor, Ronald A. Morton, Michael L. Hancock, The Journal of Urology	2011	29
Toremifene citrate versus placebo for treatment of bone loss and other complications of androgen deprivation therapy in patients with prostate cancer M. S. Steiner, Anthony Patterson, Ron Israeli, Journal of Clinical Oncology PharmacotherapyOsteoporosisPre-clinical PharmacologyBone DiseaseBone Loss	2004	25

Page 1